Rocket Pharmaceuticals Inc
RCKT
Company Profile
Business description
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Contact
9 Cedarbrook Drive
CranburyNJ08512
USAT: +1 609 659-8001
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
299
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
stocks
Bapcor is paying for the sins of its past
Shares plunged over 17% after reporting disappointing results.
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,393.00 | 19.30 | 0.21% |
CAC 40 | 8,206.07 | 17.48 | 0.21% |
DAX 40 | 24,258.80 | 427.81 | 1.80% |
Dow JONES (US) | 46,706.58 | 515.97 | 1.12% |
FTSE 100 | 9,403.57 | 49.00 | 0.52% |
HKSE | 25,858.83 | 611.73 | 2.42% |
NASDAQ | 22,990.54 | 310.57 | 1.37% |
Nikkei 225 | 49,648.61 | 463.11 | 0.94% |
NZX 50 Index | 13,324.48 | 20.48 | -0.15% |
S&P 500 | 6,735.13 | 71.12 | 1.07% |
S&P/ASX 200 | 9,091.50 | 15.60 | 0.17% |
SSE Composite Index | 3,863.89 | 24.14 | 0.63% |